Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology
+$0.88 today
- Market cap
- $4.84B
- Beta
- 0.35
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$5.26
Volume 2.71M
Average 2.15M
COGT EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Cogent Biosciences, Inc.NASDAQ: COGT
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) remains negative
Q2 FY2026 EPS (Diluted) was -$0.52, compared with -$0.65 a year earlier. Trailing-twelve-month EPS (Diluted) was -$2.31.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 9 analysts of -$2.25 (-10.1%) for the fiscal year ending Dec 2026, a slowdown from the +12.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$0.52+8.8% QoQ
- Last fiscal yearDec 2025
- -$2.04+12.1% YoY
- LTMJun 2026
- -$2.31+8.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +20.0% | +1.2% | -18.8 pp |
| 1 year | +12.1% | -10.1% | -22.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (2.04) USD
- Year-over-year change
- +12.1%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.04) | +12.1% |
| FY2024 | 2024-12-31 | (2.32) | +4.1% |
| FY2023 | 2023-12-31 | (2.42) | -7.1% |
| FY2022 | 2022-12-31 | (2.26) | -22.2% |
| FY2021 | 2021-12-31 | (1.85) | — |
EPS (Diluted) vs competitors
How COGT compares with its peers on the latest reported figures
- COGT's LTM Jun 2026 EPS (Diluted) of -$2.31 is the 5th highest of the 10 companies compared; the peer median is -$2.75.
- Its year-over-year change of +8.7% is the 5th highest of 10, against a peer median of +6.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $7.85 | +78.4% | +61.6% | |
| LTM Aug 2026 | $2.31 | +177.8% | — | |
| LTM Sep 2026 | -$1.38 | -51.6% | — | |
| LTM Mar 2026 | -$1.6 | +55.4% | — | |
| LTM Jun 2026 | -$2.31 | +8.7% | — | |
| LTM Mar 2026 | -$2.75 | -4396.9% | — | |
| LTM Mar 2026 | -$2.8 | +27.6% | — | |
| LTM Mar 2026 | -$3.35 | -59.5% | — | |
| LTM Mar 2026 | -$3.53 | +6.4% | — | |
| LTM Jun 2026 | -$3.93 | -20.6% | — | |
| Peer median (excluding COGT) | -$2.75 | +6.4% | +61.6% | |
Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.62M |
| Gross Profit | 0 | 0 | 0 | 0 | (4.62M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 55.91M | 121.63M | 173.76M | 232.66M | 269.78M |
| Selling, General & Admin | 19.64M | 26.21M | 34.38M | 43.28M | 63.58M |
| Operating Expenses | 75.55M | 147.84M | 208.13M | 275.94M | 328.74M |
| Depreciation & Amortization | 147K | 5.88M | 3.59M | 4.35M | 4.58M |
| EBITDA | (72.13M) | (130.37M) | (188.82M) | (251.51M) | (321.29M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (75.55M) | (147.84M) | (208.13M) | (275.94M) | (333.36M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 467K | 3.99M | 13.08M | 18.09M | 14.69M |
| Interest Expense | 0 | 3.99M | 0 | 0 | 3.06M |
| Other Income / Expenses | 3.28M | 7.6M | 15.72M | 20.08M | 4.43M |
| Income Before Tax | (72.27M) | (140.24M) | (192.41M) | (255.86M) | (328.94M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.27M) | (140.24M) | (192.41M) | (255.86M) | (328.94M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.85) | (2.26) | (2.42) | (2.32) | (2.04) |
| EPS (Diluted) | (1.85) | (2.26) | (2.42) | (2.32) | (2.04) |
| Weighted Avg Shares | 38.73M | 58.74M | 79.66M | 110.46M | 160.98M |
| Weighted Avg Shares (Diluted) | 38.73M | 58.74M | 79.66M | 110.46M | 160.98M |
Cogent Biosciences, Inc.
NASDAQ:COGT
Intrinsic Alpha fair value
Locked
Current Price
$27.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.